◼ Archived
Business
🔮 fades ✓
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
Bristol Myers Squibb
10 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Bristol Myers Squibb
This hub groups 10 separate news trends connected to Bristol Myers Squibb, spanning July 21, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 73 article observations and 70 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
Bristol Myers Squibb ends blood‑cancer deal, prompting Cellares to cut 100 jobs and reorganize.
◼ Archived
Business
🔮 fades ✓
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
Bristol Myers Squibb's new multiple myeloma drug Zenbexus™ debuts as a novel treatment class, but the company faces financial pressure from generic competition.
◼ Archived
Business
Bristol Myers to build $2.3 billion manufacturing site in Houston
Bristol Myers Squibb is investing $2.3 billion in a new manufacturing site in Houston, Texas.
◼ Archived
Business
🔮 fades ✓
Pharma giant bets $2.3B on massive new Houston campus
Bristol Myers Squibb is investing $2.3 billion in a new manufacturing campus in Houston, Texas.
◼ Archived
Business
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
AstraZeneca's stock surged 6% after a report of merger talks with Bristol Myers Squibb was denied.
◼ Archived
Business
Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market
Two pharmaceutical giants are in merger talks, potentially reshaping the industry.
◼ Archived
Business
🔮 fades ✓
AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports
AstraZeneca investors react to potential $400 billion merger with Bristol Myers Squibb
◼ Archived
Business
🔮 fades ✓
AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
AstraZeneca and Bristol Myers Squibb are in talks for a $400bn merger, a deal that would reshape the pharmaceutical industry
◼ Archived
Business
🔮 fades ✓
Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
Bristol Myers Squibb is partnering with Nvidia to build what it claims will be the life sciences industry's most powerful AI supercomputer.